Abstracts

BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS

Recent studies have described that treatment with rilpivirine (RPV) induces antifibrotic effects in various models of chronic liver disease1. Our objective was to analyse whether HIV-infected patients with some degree of liver stiffness measured by transition elastography (TE) and treated with RPV-based regimens showed any improvement.  1. Martí-Rodrigo A, Alegre F, Moragrega ÁB, et al. Gut epub ahead…

HEPATIC STEATOSIS ASSOCIATED WITH EXPOSURE TO ELVITEGRAVIR AND RALTEGRAVIR

Treatment with integrase strand transfer inhibitors and nucleotide analogues may be associated with weight gain in people living with HIV (PLWH). Overweight is associated with fatty liver. Here we studied the association of antiretrovirals and moderate-severe hepatic steatosis.  PLWH without prior or current viral hepatitis or alcohol intake above recommendations were included in 2015-16. Liver steatosis was…

AN RCT OF RALTEGRAVIR- VERSUS EFAVIRENZ-BASED ART IN HIV-HCV COINFECTION

Drug induced liver injury following initiation of ART is more common in HIV/HCV coinfected patients; however comparative data on hepatotoxicity of ARVs used in this population are lacking as HIV/HCV coinfected patients are largely excluded from clinical trials. We compared hepatotoxicity, virological, and clinical outcomes between raltegravir (RAL)- and efavirenz (EFV)-based ART in HIV/HCV coinfected…

INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID

Numerous studies show a link between visceral adiposity and metabolic disorders. Fatty liver is an established risk factor for cirrhosis and liver cancer and is increasing among aging persons living with HIV (PWH).  We investigated the prevalence and correlates of hepatic steatosis, assessed non-invasively by elastography with controlled attenuation parameter (CAP), in a community cohort of…